Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Coronaviridae Infections Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Coronaviridae Infections Overview | 11 | 1 |
| Pipeline Products for Coronaviridae Infections Comparative Analysis | 12 | 1 |
| Coronaviridae Infections Therapeutics under Development by Companies | 13 | 2 |
| Coronaviridae Infections Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Coronaviridae Infections Pipeline Products Glance | 16 | 3 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Coronaviridae Infections Products under Development by Companies | 19 | 2 |
| Coronaviridae Infections Products under Investigation by Universities/Institutes | 21 | 1 |
| Coronaviridae Infections Companies Involved in Therapeutics Development | 22 | 16 |
| AstraZeneca Plc | 22 | 1 |
| CEL-SCI Corporation | 23 | 1 |
| GeneCure LLC | 24 | 1 |
| Gilead Sciences, Inc. | 25 | 1 |
| Hemispherx Biopharma, Inc. | 26 | 1 |
| Humabs BioMed SA | 27 | 1 |
| Inovio Pharmaceuticals, Inc. | 28 | 1 |
| Kineta, Inc. | 29 | 1 |
| Nanotherapeutics, Inc. | 30 | 1 |
| NanoViricides, Inc. | 31 | 1 |
| Novavax, Inc. | 32 | 1 |
| Organic Vaccines | 33 | 1 |
| Phelix Therapeutics, LLC | 34 | 1 |
| Planet Biotechnology Inc. | 35 | 1 |
| Protein Sciences Corporation | 36 | 1 |
| Regeneron Pharmaceuticals Inc | 37 | 1 |
| Coronaviridae Infections Therapeutics Assessment | 38 | 10 |
| Assessment by Monotherapy Products | 38 | 1 |
| Assessment by Combination Products | 39 | 1 |
| Assessment by Target | 40 | 2 |
| Assessment by Mechanism of Action | 42 | 2 |
| Assessment by Route of Administration | 44 | 2 |
| Assessment by Molecule Type | 46 | 2 |
| Drug Profiles | 48 | 39 |
| CEL-1000 Drug Profile | 48 | 2 |
| D-3252 Drug Profile | 50 | 1 |
| Drugs to Inhibit Cathepsin L for Infectious Diseases Drug Profile | 51 | 1 |
| FBR-001 Drug Profile | 52 | 1 |
| FDX-000 Drug Profile | 53 | 1 |
| Gene Therapy for Severe Acute Respiratory Syndrome Drug Profile | 54 | 1 |
| GS-5734 Drug Profile | 55 | 1 |
| INO-4500 Drug Profile | 56 | 2 |
| interferon alfa-n3 Drug Profile | 58 | 4 |
| interferon beta-1a Drug Profile | 62 | 3 |
| KIN-1400 Drug Profile | 65 | 2 |
| LCA-60 Drug Profile | 67 | 1 |
| Middle East respiratory syndrome coronavirus vaccine Drug Profile | 68 | 1 |
| Middle East respiratory syndrome coronavirus vaccine Drug Profile | 69 | 1 |
| Middle East respiratory syndrome coronavirus vaccine Drug Profile | 70 | 1 |
| Middle East respiratory syndrome vaccine Drug Profile | 71 | 1 |
| Middle East respiratory syndrome vaccine Drug Profile | 72 | 1 |
| Middle East respiratory syndrome vaccine + severe acute respiratory syndrome vaccine Drug Profile | 73 | 1 |
| ML-188 Drug Profile | 74 | 1 |
| Monoclonal Antibody for Coronavirus Infection Drug Profile | 75 | 1 |
| Monoclonal Antibody for SARS Virus Infections Drug Profile | 76 | 1 |
| RBD-219N1 Drug Profile | 77 | 1 |
| REGN-3048 Drug Profile | 78 | 1 |
| REGN-3051 Drug Profile | 79 | 1 |
| SAB-301 Drug Profile | 80 | 1 |
| SARS (virus like particle) vaccine Drug Profile | 81 | 1 |
| severe acute respiratory syndrome vaccine Drug Profile | 82 | 1 |
| Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection Drug Profile | 83 | 1 |
| Small Molecules for Viral Infections Drug Profile | 84 | 1 |
| Small Molecules to Inhibit 3CLpro for Coronavirus Infections Drug Profile | 85 | 1 |
| SSYA-10001 Drug Profile | 86 | 1 |
| Coronaviridae Infections Dormant Projects | 87 | 3 |
| Coronaviridae Infections Discontinued Products | 90 | 1 |
| Coronaviridae Infections Product Development Milestones | 91 | 9 |
| Featured News &Press Releases | 91 | 1 |
| Aug 11, 2016: Phase I Clinical Trials Underway for First MERS Treatment | 91 | 1 |
| Aug 08, 2016: GeneOne Life Science Announces Full Enrollment of First-In-Human Study of MERS Vaccine | 92 | 1 |
| Jan 20, 2016: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection as a Treatment of Middle East Respiratory Syndrome | 92 | 1 |
| Nov 19, 2015: GeneOne Life Science and Inovio Pharmaceuticals MERS Vaccine Approved for First-in-Human Study | 93 | 1 |
| Oct 19, 2015: Inovio and Partner Advance MERS Vaccine | 93 | 1 |
| Oct 19, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients with Middle East Respiratory Syndrome | 93 | 1 |
| Jul 28, 2015: PNAS Paper Details Efficacy Of A Potent, Fully Human Antibody For The Treatment Of MERS | 94 | 1 |
| Jul 15, 2015: Hemispherx Biopharma Europe Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection for Treatment of Middle East Respiratory Syndrome | 95 | 1 |
| Jun 22, 2015: MERS coronavirus: Candidate vaccine gears up for clinical trials | 95 | 1 |
| Jun 04, 2015: Kineta s Novel Broad Spectrum Antivirals Trigger Effective Natural Immune Response to Flu and Respiratory Virus Infections | 96 | 1 |
| Jun 16, 2014: Hemispherx Announces New Publication With Potential Insight Into High Mortality Rate in Middle Eastern Respiratory Syndrome (MERS) | 97 | 1 |
| Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus | 98 | 1 |
| Jun 06, 2013: Novavax Produces New Vaccine Candidate To Fight MERS-CoV Infection | 99 | 1 |
| Appendix | 100 | 2 |
| Methodology | 100 | 1 |
| Coverage | 100 | 1 |
| Secondary Research | 100 | 1 |
| Primary Research | 100 | 1 |
| Expert Panel Validation | 100 | 1 |
| Contact Us | 100 | 1 |
| Disclaimer | 101 | 1 |
